[go: up one dir, main page]

AU2001292881A1 - Use of recombinant gene delivery vectors for treating or preventing diseases of the eye - Google Patents

Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Info

Publication number
AU2001292881A1
AU2001292881A1 AU2001292881A AU9288101A AU2001292881A1 AU 2001292881 A1 AU2001292881 A1 AU 2001292881A1 AU 2001292881 A AU2001292881 A AU 2001292881A AU 9288101 A AU9288101 A AU 9288101A AU 2001292881 A1 AU2001292881 A1 AU 2001292881A1
Authority
AU
Australia
Prior art keywords
eye
treating
gene delivery
recombinant gene
preventing diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292881A
Inventor
Adriana Di Polo
Varavani J. Dwarki
John G. Flannery
Dana Lau
William C. Manning
Laura H. Mcgee
Sheldon S. Miller
Katherine Rendahl
Fei Wang
Shang-Zhen Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/665,493 external-priority patent/US6943153B1/en
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2001292881A1 publication Critical patent/AU2001292881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001292881A 2000-09-20 2001-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye Abandoned AU2001292881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/665,493 US6943153B1 (en) 1999-03-15 2000-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US09/665,493 2000-09-20
PCT/US2001/029480 WO2002024234A2 (en) 2000-09-20 2001-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Publications (1)

Publication Number Publication Date
AU2001292881A1 true AU2001292881A1 (en) 2002-04-02

Family

ID=24670335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292881A Abandoned AU2001292881A1 (en) 2000-09-20 2001-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Country Status (2)

Country Link
AU (1) AU2001292881A1 (en)
WO (1) WO2002024234A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066780A2 (en) 1999-04-30 2000-11-09 University Of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
US7291483B2 (en) 1999-07-27 2007-11-06 Curagen Corporation FGF-CX polynucleotide sequences and methods of producing same
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US7056885B1 (en) 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
JP2005500035A (en) * 2001-06-15 2005-01-06 キュラジェン コーポレイション Novel fibroblast growth factor and nucleic acid encoding it
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
AU2003295312B2 (en) 2002-05-01 2008-08-14 University Of Florida Research Foundation, Inc. Improved rAAV expression systems for genetic modification of specific capsid proteins
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
EP1567198A4 (en) * 2002-12-02 2006-05-31 Genvec Inc Materials and methods for treating ocular-related disorders
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
DE602005021811D1 (en) 2004-09-13 2010-07-22 Genzyme Corp MULTI-MORE CONSTRUCTS
JP2008543879A (en) 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド LKKTET and / or LKKTNT peptide compositions and methods
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
ES2329636B2 (en) 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) USE OF PEDF FACTOR TO INDUCE MOTHER CELLS SELF-RENEWAL
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
PL2601214T3 (en) 2010-08-06 2018-05-30 Genzyme Corporation Vegf antagonist compositions and uses thereof
US10973931B2 (en) 2014-09-16 2021-04-13 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
CN104468061B (en) * 2014-11-25 2019-08-20 厦门雅迅网络股份有限公司 A kind of method and system of real-time reliable data transmission under low-speed network environment
WO2016110518A1 (en) 2015-01-07 2016-07-14 Universitat Autònoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
CN106591370A (en) * 2015-10-19 2017-04-26 南京华贞生物医药科技有限公司 Virus vector for treating autoimmune related diseases and diabetes, construction method and applications thereof
US20190352615A1 (en) * 2016-12-22 2019-11-21 Blue Sky Vaccines Gmbh Method for purifying virus
IL270882B2 (en) * 2017-05-24 2024-02-01 Univ Barcelona Autonoma Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
EP3630160A1 (en) * 2017-05-24 2020-04-08 Universitat Autònoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
KR102205830B1 (en) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 Pharmaceutical Composition for Treating Macular Degeneration Containing AAV Including cDNA of Soluble VEGFR Variant
EP4616865A1 (en) * 2024-03-13 2025-09-17 Dompe' Farmaceutici SpA Bdnf for the treatment of rhodopsin-mediated retinitis pigmentosa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
JP2001501471A (en) * 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド Gene therapy for inhibiting angiogenesis
EP1045921A2 (en) * 1998-01-16 2000-10-25 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
WO2000015822A1 (en) * 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
JP2002539176A (en) * 1999-03-15 2002-11-19 カイロン コーポレイション Use of a recombinant gene delivery vector to treat or prevent ocular diseases
WO2000071582A1 (en) * 1999-05-20 2000-11-30 Human Genome Sciences, Inc. Fibroblast growth factor 14

Also Published As

Publication number Publication date
WO2002024234A3 (en) 2002-12-27
WO2002024234A2 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001292881A1 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU3755900A (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
IL152549A0 (en) Vectors for ocular transduction and use thereof for genetic therapy
AU2002322719A1 (en) Delivery of therapeutic capable agents
MXPA03007590A (en) Compositions and methods for enhancing drug delivery across and into ocular tissues.
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
AU2003234529A1 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
HUP0401605A3 (en) Integrin inhibitors for the treatment of eye diseases
AU2002325683A1 (en) Recombinant vector derived from adeno-associated virus for gene therapy
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2001292125A1 (en) Genetic factors affecting the outcome of viral infections
IL150455A0 (en) Controlling offispring's sex by targeting transgenes onto the sex chromosomes
AU2003285346A1 (en) Regulatory elements in the 5' region of the vr1 gene
AU2003273983A8 (en) Viral vectors and the use of the same for gene therapy
AU2002240942A1 (en) Improved delivery of benefit agents
AU5295500A (en) Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU2002360696A1 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
AU2003284703A1 (en) Recombinant peptide vector comprising the gene for treatment for autoimmune diseases.
AU1935501A (en) Id protein inhibitors for treating ocular diseases
AU2002325684A1 (en) Recombinant vectors derived from adeno-associated virus expressing tam67 for gene therapy
AU2002319719A1 (en) Delivery of therapeutic capable agents
EP1370138A4 (en) Gene therapy for neurological tissues